Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study
This study aimed to assess whether standard-dose Betahistine (48 mg daily) exerts an effect upon the degree of endolymphatic hydrops in patients with Menière’s disease using a retrospective case series in the setting of a tertiary neurotology referral centre. In six patients with definite unilateral Menière’s disease, the degree of cochlear and vestibular endolymphatic hydrops was assessed before and after treatment with a standard dose of Betahistine (48 mg daily), using high-resolution 3 T MR imaging after intratympanic contrast medium application. The treatment duration was 3–7 months (mean 5 months), and the patients were followed-up for 6–29 months (mean 11 months). In the study cohort, the standard dose of Betahistine did not have an MR morphologically measurable beneficial effect on the degree of endolymphatic hydrops. The results indicated no effect of standard-dose Betahistine on endolymphatic hydrops found on high-resolution MR imaging. Possible explanations are: (1) insufficient dosage or duration of treatment with betahistine, (2) insufficient resolution of the MR imaging technique, and (3) insufficient length of follow-up. Further studies addressing these issues are warranted.
KeywordsMenière’s disease Endolymphatic hydrops Betahistine Magnetic resonance imaging
This study was supported by the Federal German Ministry of Education and Research (Grant no. 01EO0901). The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of interest
None of the authors have a conflict of interest to declare.
- 1.Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. (1995) Otolaryngol Head Neck Surg 113:181-185Google Scholar
- 9.James AL, Burton MJ (2001) Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev (1):CD001873Google Scholar
- 12.Louza J, Flatz W, Krause E, Gürkov R (2012) Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Meniere’s disease. Am J Otolaryngol [Epub ahead of print]Google Scholar
- 17.Fang ZM, Chen X, Gu X, Liu Y, Zhang R, Cao DR, He HG (2012) A new magnetic resonance imaging scoring system for perilymphatic space appearance after intratympanic gadolinium injection, and its clinical application. J Laryngol Otol 126(5):454–459Google Scholar